Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Dermata Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 7 | 6 | −1 |
| Shares | 75.4K | 32.8K | −42.6K (−56.5%) |
| Value | $29.8K | $78.3K | +$48.4K (+162.5%) |
New holders (3)
Institutions that held Dermata Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 28,000 | $66.9K | 0.00% |
| UBS Group AG | 1,705 | $4.08K | 0.00% |
| Bank of America Corp | 3 | $7 | 0.00% |
Sold out (4)
Institutions that held Dermata Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Two Sigma Securities, LLC | 19,968 | $8.20K |
| Citadel Advisors LLC | 17,490 | $7.03K |
| Geode Capital Management, LLC | 12,237 | $4.92K |
| Northwestern Mutual Wealth Management Co | 14 | $6 |